Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff

Astellas President and CEO Naoki Okamura Astellas Pharma is set to capitalize on an eye drug to be acquired through the buyout of Iveric Bio as a “third pillar” of its business that will make up for an anticipated patent...read more